Cargando…

Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors

CONTEXT: Mild-to-moderate bleeding disorders in haemophilia are primarily treated via recombinant activated factor VII a (rFVIIa) or activated prothrombin complex concentrate (aPCC). However, the efficacy of each bypassing agents may vary and none of them is universally effective. EVIDENCE ACQUISITI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golestani, Mina, Eshghi, Peyman, Rasekh, Hamid Reza, Cheraghali, Abdol Majid, Salamzadeh, Jamshid, Imani, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341353/ https://www.ncbi.nlm.nih.gov/pubmed/25763245 http://dx.doi.org/10.5812/ircmj.24551

Ejemplares similares

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran
por: Golestani, Mina, et al.
Publicado: (2016)

Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran
por: Rasekh, Hamid Reza, et al.
Publicado: (2011)

Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review
por: Chaudhury, Ateefa, et al.
Publicado: (2020)

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
por: Meeks, Shannon L., et al.
Publicado: (2019)

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
por: Escobar, Miguel, et al.
Publicado: (2021)

S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
por: Kenet, Gili, et al.
Publicado: (2023)

Haemophilia in the developing countries: the Iranian experience
por: Eshghi, Peyman, et al.
Publicado: (2010)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

The Availability and Affordability of Cardiovascular Medicines for Secondary Prevention in Tehran Province (Iran)
por: Vasheghani Farahani, Ali, et al.
Publicado: (2018)

Estimation of transient increases in bleeding risk associated with physical activity in children with haemophilia
por: Broderick, Carolyn R, et al.
Publicado: (2008)

Association of factor expression levels with annual bleeding rate in people with haemophilia B
por: Burke, Tom, et al.
Publicado: (2022)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Implications of Confidential Unit Exclusion in Providing Sufficient Safe Blood for the National Health System
por: Cheraghali, Abdol Majid
Publicado: (2011)

Blood safety concerns in the Eastern Mediterranean region
por: Cheraghali, Abdol Majid
Publicado: (2011)

Cost effectiveness of Iran national plasma contract fractionation program
por: Cheraghali, Abdol Majid
Publicado: (2012)

Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry
por: Cheraghali, Abdol Majid
Publicado: (2012)

Impacts of international sanctions on Iranian pharmaceutical market
por: Cheraghali, Abdol Majid
Publicado: (2013)

Trends in Iran Pharmaceutical Market
por: Cheraghali, Abdol Majid
Publicado: (2017)

Budget impact analysis of conversion from cyclosporine to sirolimus as immunosuppressive medication in renal transplantation therapy
por: Foroutan, Naghmeh, et al.
Publicado: (2013)

Relationship between bleeding episodes, health‐related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study
por: O'Hara, Jamie, et al.
Publicado: (2022)

Costs of Treatment after Renal Transplantation: Is it Worth to Pay More?
por: Salamzadeh, Jamshid, et al.
Publicado: (2014)

Prevention and Management of Bleeding Episodes in Children with Hemophilia
por: Ljung, Rolf C. R.
Publicado: (2018)

The endothelial specific isoform of type XVIII collagen correlates to annual bleeding rate in haemophilia patients
por: Kjeld, Nadja Gad, et al.
Publicado: (2018)

Clinical management of woman with bleeding disorders: A survey among European haemophilia treatment centres
por: van Galen, Karin P. M., et al.
Publicado: (2020)

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients
por: Ljung, Rolf, et al.
Publicado: (2018)

An algorithmic approach to gastrointestinal bleeding in patients receiving antithrombotic agents
por: Sadeghi, Amir, et al.
Publicado: (2020)

Successful Control of Massive Bleeding in a Child with Burkitt's Lymphoma via a Biosimilar Recombinant Activated Factor VII (AryoSeven™)
por: Goudarzi Pour, Kourosh, et al.
Publicado: (2016)

Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia
por: ALMAGRO, D, et al.
Publicado: (2011)

How to Manage a Patient with Haemophilia and ACS Requiring PCI: A Battle between Bleeding and Thrombosis
por: Theodoropoulos, Konstantinos C., et al.
Publicado: (2021)

Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders
por: Kaczmarek, Radoslaw, et al.
Publicado: (2021)

A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen
por: Kennedy, Megan, et al.
Publicado: (2021)

Policies and measures implemented to reduce the impact of international sanctions on Iran's pharmaceutical sector
por: Emami, Farideh, et al.
Publicado: (2022)

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery
por: Jiménez‐Yuste, Victor, et al.
Publicado: (2021)

To Bleed or Not to Bleed
por: Iskander, Peter A, et al.
Publicado: (2023)

Complement activation and excessive bleeding in cardiopulmonary bypass surgery
por: Iribarren, J, et al.
Publicado: (2007)

Factors associated with excessive bleeding in cardiopulmonary bypass patients
por: Jimenez Rivera, J, et al.
Publicado: (2006)

Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy
por: Shafer, F, et al.
Publicado: (2014)

Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria
por: Ay, Cihan, et al.
Publicado: (2021)

Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues
por: Weyand, Angela C., et al.
Publicado: (2022)

Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A
por: Knöbl, Paul
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9kpgkkq583qji3dis1o6rmgikh